January 8, 2024 4:35pm
From an initial a.m. downdraft as many update pipelines, milestones, clinical stages and strategic priorities <see list in The Bottom Line> to an ascension of value
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Pre-open Indications: 5 Hits and 2 Miss
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.
Never leave an investor uninformed! A trusted source of factual reporting!
With a sigh of relief today, I answer/qualify one question, what happen today in the cell and gene therapy sector and market
Monday: The Dow closed UP +216.90 points or +0.58%, the S&P closed UP +66.30 points or +1.41% while the Nasdaq closed UP +319.70 points or +2.20%
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes closed to the upside after a jockeying a.m. and afternoon as Investors are buying the dip; while the yield on the 10-year Treasury yield lost nearly 4 basis points to 3.991%.
Economic Data Docket: Mortgage fell back below 7% in December. Rates, however, are still twice what they were three years ago.
Pre-Open: RegMed Investors’ (RMi) pre-open: “let the music of JPM Healthcare conference begin. The name of the game this week, dominates institution’s attention … Who will have a seat when the presentations begin, which will benefit from the investment gamut after when the music stops?” … https://www.regmedinvestors.com/articles/13276
Pre-Open Indications: 5 Hits < Alnylam Pharmaceuticals (ALNY +$7.45), Beam Therapeutics (BEAM +$1.79), Caribou Bioscience (CRBU +$0.92), CRISPR Therapeutics (CRSP +$2.02), Verve Therapeutics (VERV +$0.61)> 2 Miss < AxoGen (AXGN +$0.04), Sage Therapeutics (SAGE +$3.63)>
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …
- Monday’s advance/decline line was negative at the open with 14 incliners, 20 decliners and 1 flat, ending with a positive close of 28 incliners, 6 decliners and 1 flat
Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:
Q1/24: 1 holiday, 2 negative and 3 positive closes
Q4:
- 1 holiday, 10 negative and 10 positive closes
- November – 11 positives, 1 holiday and 10 negative closes
- October – 12 negative and 10 positive closes
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB was up +2.40% and the XBI was up +4.61%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was down -0.31 point or -2.32% at 13.03
Monday’s Closing Down (6 of 6):
- Regenxbio (RGNX -$2.01 after Friday’s -$0.95),
- Homology Medicine (FIXX -$0.0190),
- Agenus (AGEN -$0.0180 after Friday’s +$0.0019)
- Graphite Bio (GRPH -$0.01)
- Mesoblast (MESO -$0.01 after Friday’s +$0.01)
- Bellicum Pharmaceuticals (BLCM -$0.0050)
Flat (1):
- Harvard Apparatus RN (HRGN)
Monday’s Closing Up (10 of 28):
- Alnylam Pharmaceuticals (ALNY +$7.45 after Friday’s -$2.93
- Sage Therapeutics (SAGE +$3.63 after Friday’s +$0.34
- Blueprint Medicine (BPMC +$2.34 after Friday’s -$2.24
- Vericel (VCEL +$2.27 after Friday’s -$1.48
- Ultragenyx Pharmaceuticals (RARE +$2.18 after Friday’s +$0.51
- CRISPR Therapeutics (CRSP +$2.02 after Friday’s -$1.27
- Beam Therapeutics (BEAM +$1.79 after Friday’s +$0.05),
- Ionis Pharmaceuticals (IONS +$1.62 after Friday’s -$0.78)
- BioLife Solutions (BLFS +$1.59),
- Intellia Therapeutics (NTLA +$1.44 after Friday’s -$0.89),
Q1/24 – January
- (1/8) Monday closed positive with 28 incliners, 6 decliners and 1 flat
The BOTTOM LINE: Back to the good old days of JPM Healthcare conference boosting appeal to cell and gene therapy companies …
As the Nasdaq gained more than 2% for the first time in 2024 – today.
But remember, “News, financings, Q4 earnings LPS (loss-per-share) and “runways” will be the under-current or headwind for January through March 2024. Pricing for gene therapies will continue to dominate share ascensions and downfalls!” <me>
Odd % thoughts:
- The daily upside jumped Monday from +0.33% to +19.09% after Friday from +0.24% to 26.67% and Thursday’s +0.30% to +9% and the downside
- The daily down slide Monday -0.36% to -12.22% after Friday’s and down slide of -18.36% to -0.16% and Thursday’s-0.44% to -7.85%
Monday’s backdrop: released highlights of pipeline updates as JPM Healthcare conference evolves …
Precigen (PGEN):
Editas Medicine (EDIT):
BioLife Solutions (BLFS):
bluebird bio (BLUE)
Blueprint Medicine (BPMC):
Fate Therapeutics (FATE):
Ionis Pharmaceuticals (IONS):
CRISPR Therapeutics (CRSP):
Sage Therapeutics (SAGE):
Beam therapeutics (BEAM):
Alnylam Pharmaceuticals (ALNY):
Ultragenyx Pharmaceuticals (RARE):
Compass Therapeutics (CMPX):
The top three (3) performing in the session:
- Monday: Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE) and Blueprint Medicine (BPMC)
The worst three (3) in the session:
- Monday: Regenxbio (RGNX), Homology Medicine (FIXX) and Agenus (AGEN)
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
